Sarepta (SRPT) Conditional-Approval Thesis Unchanged, Roth Capital Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Needham & Company Maintain High Conviction for Sarepta (SRPT) Eteplirsen Approval
November 6, 2015 6:53 AM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they maintain high conviction in Eteplirsen approval.
Messer commented, "SRPT shares have pulled back from recent highs due to concerns that etelpirsen's later than expected... More
Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c
November 5, 2015 7:04 AM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($1.11), $0.07 better than the analyst estimate of ($1.18).
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
... More